ProFound Therapeutics founding team

Flag­ship's lat­est biotech could turn some of the thou­sands of new pro­teins it dis­cov­ered in­to ther­a­pies — and it has $75M to start

Flag­ship Pi­o­neer­ing, the in­cu­ba­tor of Mod­er­na and dozens of oth­er biotechs, says it has land­ed up­on tens of thou­sands of pre­vi­ous­ly undis­cov­ered hu­man pro­teins. The VC shop wants to po­ten­tial­ly turn them in­to ther­a­peu­tics.

Like oth­er drug de­vel­op­ers that have turned pro­teins in­to ther­a­peu­tics (think in­sulin for di­a­betes), Flag­ship’s lat­est cre­ation, Pro­Found Ther­a­peu­tics, wants to tap in­to this new trove of pro­teins as part of its mis­sion to treat in­di­ca­tions rang­ing from rare dis­eases to can­cer to im­muno­log­i­cal dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA